Study | Location | Study design | Gender (n, male) | Agent | Follow-up period | Samle size | Treatment | Control |
---|---|---|---|---|---|---|---|---|
Infection/Total | Infection/Total | |||||||
Lu et al. 2003 [28] | China | Prosepctive | 72 | 3rd cephalosporin | 7Â years | 118 | 0/61 | 0/57 |
Guo et al. 2005 [27] | China | Prosepctive | 101 | Cefazolin | 2Â years | 178 | 2/90 | 0/88 |
Lakkireddy et al. 2005 [16] | America | Retrospective | 1718 | Povidone-iodine | 8Â years | 2564 | 10/1359 | 8/1205 |
Xia et al. 2007 [29] | China | Prosepctive | 66 | Gentamicin | 3Â years | 122 | 1/63 | 1/59 |
Zhou et al. 2010 [32] | China | Prosepctive | 155 | Cefoperazone/ Tazobactam | 1Â month | 268 | 2/84 | 9/84 |
Wang et al. 2015 [17] | China | Prosepctive | 70 | Cefazolin | >4Â weeks | 116 | 2/58 | 8/58 |
Yang 2015 [30] | China | Retrospective | 931 | Amikacin/ Gentamicin | 7Â years | 1572 | 15/1133 | 16/439 |
Zhang et al. 2016 [31] | China | Prosepctive | 77 | Cefatriaxone | 6Â months | 146 | 5/73 | 21/73 |
Lakshmanadoss et al. 2016 [33] | America | Retrospective | 134 | Clindamycin phosphate | 1Â year | 327 | 2/118 | 2/209 |
Chen et al. 2017 [26] | China | Prosepctive | 95 | Azithromycin | 1Â year | 156 | 7/78 | 17/78 |